Preclinical Research
Highlights From the 2024 American College of Toxicology 45th Annual Meeting
My fellow Altasciences colleagues and I recently attended the 2024 annual Ame
How to Decrease Your Test Article Usage in Preclinical Studies
Less is More With the Sinclair Nanopig™
Did you know that using the Sinclair Nanopig™ swine model can decrease your test article usage by up to 50% compared to the Göttingen™ minipig and dog?
Let’s get your project underway with cost-effective solutions and reliable results.
Speak with one of our experts today.
Related resources you may be interested in:
Tailored Manufacturing and Analytical Testing for Your Molecules
A CDMO You Can Count On.
From discovery to commercialization, our manufacturing team is dedicated to delivering high-quality and FDA-compliant products, every time.
Discover our full range of drug development, manufacturing, and analytical testing services for oral solid dosage forms, injectables, creams, and gels―including the shipping and handling of highly potent compounds and controlled substances.
With over 25 years of experience, in-house R&D and formulation laboratories, innovative platforms and technology, and an exceptional team of scientists, we are committed to providing you with the best manufacturing solutions for your program.
You can count on us!
Speak with one of our experts today to get started.
Related resources that may interest you:
Fast Track Your 2025 Drug Development Program
Get a Head Start on Your Preclinical Studies
With four strategically placed preclinical research facilities throughout North America, we can get your investigational new drug (IND) and clinical trial application (CTA) studies underway in 8-10 weeks!
We offer a full range of in vivo non-GLP and GLP preclinical studies in both rodent and non-rodent species, to assess the safety of your small and large molecules in support of upcoming first-in-human clinical trials.
Our IND/CTA-enabling studies include:
- lead optimization
- preclinical pharmacology
- dose range finding
- pivotal toxicology (acute, sub-chronic, chronic, carcinogenicity)
- safety pharmacology
Time is of the essence―let’s get started!
Related resources that may interest you:
- eBook: Nonclinical Safety Testing Guide
- Webinar: Selecting the Right Species for Your Toxicology Program
- Scientific Journal: Achieving Optimal Preclinical Formulation and Drug Product Manufacture
From AAV to Biomarkers—Your 2025 Roadmap
Support for Your Early-Phase Gene Therapy Program
At Altasciences, we are committed to advancing gene therapies with precision and efficiency. In addition to hundreds of pre-screened AAV nonhuman primates (NHPs) available for gene therapy programs and decades of bioanalytical, nonclinical, and clinical expertise―we’ve compiled a comprehensive list of resources below:
A Comprehensive Guide to Gene Therapy and Improving AAV Efficiency
Learn more about our track record, expertise in navigating regulatory requirements, and how we ensure the safety and efficacy of AAV-based therapies (three case studies included).
In-House AAV Pre-Screening
Detailed information on our in-house AAV pre-screening methods for removing nonhuman primates from toxicology studies if they have antibodies against AAV8 serotypes. It covers two main assays: total antibody screening (TAb) and neutralizing antibody screening (NAb).
Expert Insights on Cell and Gene Therapy Development
This scientific journal reviews considerations for nonclinical cell and gene therapy development, including expert approaches to mitigate complex challenges, improve study efficiency, and maximize translational opportunities to first-in-human trials.
Altasciences’ Biomarkers by Indication
Our expertise in biomarker analysis supports critical go/no-go decision making by providing insight into a drug’s efficacy, safety, and mechanism of action. Assessed early in the drug development process, biomarker assays can validate targets and identify potential toxicity.
Ready to get your gene therapy development program started? Speak with one of our experts.
Get Started on Your Gene Therapy Preclinical Studies Today!
Our Sacramento Team is Ready to Support Your Next Gene Therapy NHP Study
With over 31,000 square feet of space and 20 animal rooms, our state-of-the-art preclinical facility in Sacramento, California, is equipped to take on your discovery and PK/PD research needs in nonhuman primates (NHPs).
With a large population of NHPs that are pre-screened for adeno-associated viruses (AAVs), we’re ready to get started on your studies immediately.
Why wait? Speak with one of our experts today to get your project started right away!
Related resources you may be interested in:
- eBook: Nonclinical Studies in Cell and Gene Therapy
- Webinar: Nonclinical AAV Gene Therapy Development
- Video: The Evolving Landscape of Gene Therapy Research
Why Choose Our Scranton Site for Your Next Ocular Study
Unmatched Expertise at Your Fingertips
Looking for the perfect partner for your nonclinical ophthalmology studies? Check out Altasciences’ preclinical facility in Scranton, Pennsylvania. With nearly 20 years of experience in ocular research and a full-time, on-site ACVO board-certified veterinary ophthalmologist overseeing every study, you can rest assured that your studies will run efficiently and with attention to detail.
Altasciences’ ocular studies target therapeutic agents across various diseases and conditions, such as age-related macular degeneration, diabetic retinopathy, glaucoma, uveitis, corneal disorders, and many more. Our specialists use different formulations and routes of administration, including topical, subconjunctival, intracameral, intravitreal, and subretinal, to allow for optimal drug delivery and absorption in the target structure of the eye.
We look forward to hosting you at our Scranton facility soon. Speak with one of our experts today to start your study!
Related resources you may be interested in:
- Video: Scranton Facility Virtual Tour
- Podcast: Nonclinical Considerations When Developing an Ophthalmic Drug
- eBook: Safety Testing of Ophthalmic Products
- Webinar: Gene and Cell Therapy: Enhanced CNS and Ocular Delivery in Nonhuman Primates
- Webinar: Ocular Imaging Followed by Microscopic Analysis of Focal Chorioretinal Defects in Dutch-Belted Rabbits
Case Study—Gene Therapy and Stem Cell Transplantation Via MRI-Guided Intraparenchymal Delivery Into Brain Regions (Cortical and Subcortical)
How Combined CDMO and Clinical Teams Accelerate Drug Development
Streamlined Processes. Faster Approval.
In this new video, we share how our integrated teams’ combined expertise in clinical trials and manufacturing simplify the drug development process, empowering you to bring innovative therapies to market faster and, ultimately, improve patient outcomes.
Watch now to learn how our cohesive approach minimizes delays, reduces costs, and enhances collaboration.
Looking for drug development and manufacturing services? Speak with one of our experts today.
Related resources that may interest you:
- Webpage: Pharmaceutical Contract Manufacturing Services
- eBook: Advantages of Conducting Early-Phase Clinical Research in Canada
- Webinar: Overcoming Challenges in Manufacturing for Clinical Trials